论文部分内容阅读
目的观察瑞替普酶辅治心肌梗死的临床治疗效果。方法将120例心肌梗死患者随机分为试验组和对照组各60例。试验组给予瑞替普酶治疗,对照组运用尿激酶治疗,比较2组患者的治疗效果、血管通畅率以及血管通畅所需的时间。结果试验组总有效率为93.33%高于对照组的75.83%,差异有统计学意义(P<0.05)。试验组患者总血管开通率、<6h患者血管开通率、6~12h患者血管开通率均显著高于对照组患者,差异均有统计学意义(P<0.05),试验组患者血管开通用时显著短于对照组,差异有统计学意义(P<0.05)。结论瑞替普酶辅治心肌梗死能够显著提高治疗的有效率,在血管通畅率以及血管开通时间方面均优于尿激酶,具有较高的临床推广价值。
Objective To observe the clinical effect of reteplase in treating myocardial infarction. Methods 120 cases of myocardial infarction were randomly divided into experimental group and control group of 60 cases. The trial group was treated with reteplase, while the control group was treated with urokinase. The therapeutic effect, the rate of patency and the time required for patency of the two groups were compared. Results The total effective rate of the experimental group was 93.33% higher than that of the control group (75.83%), the difference was statistically significant (P <0.05). The total vessel opening rate of patients in trial group, the rate of opening of vessels in patients <6h and the rate of opening of vessels in patients of 6 ~ 12h were significantly higher than those in control group (P <0.05). The patients in trial group had shorter opening time In the control group, the difference was statistically significant (P <0.05). Conclusion Reteplase for myocardial infarction can significantly improve the efficiency of treatment, and is superior to urokinase in terms of vascular patency rate and blood vessel opening time, which has a higher clinical promotion value.